- AU$859.12m
- AU$707.52m
- AU$26.17m
- 49
- 23
- 39
- 29
Annual balance sheet for PYC Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 51.5 | 29.1 | 15.6 | 66.9 | 153 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.186 | 10.1 | 16.3 | 18 | 24.1 |
| Prepaid Expenses | |||||
| Total Current Assets | 51.8 | 39.2 | 31.9 | 85.6 | 178 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.49 | 1.63 | 1.04 | 1.57 | 1.9 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 57.9 | 45.4 | 37.2 | 91.2 | 183 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.3 | 4.39 | 8.41 | 9.11 | 12.3 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.9 | 6 | 9.42 | 10.7 | 13.7 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 53 | 39.4 | 27.7 | 80.5 | 170 |
| Total Liabilities & Shareholders' Equity | 57.9 | 45.4 | 37.2 | 91.2 | 183 |
| Total Common Shares Outstanding |